Boehringer Ingelheim reported Phase 3 results for a glucagon-targeted dual agonist showing 16.6% weight loss, while stopping short of the performance seen with established therapies. The company framed the program around improving cardiometabolic risk reduction by combining mechanisms tied to glucagon signaling with its drug’s broader pharmacology. The update also leaves open key questions that will likely shape future study design and regulatory discussions.